NCT02490475 - A Multiple-Dose Study of RhuMab 2C4 and Docetaxel in the Treatment of Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions

Solid Tumor

Interventions

DRUG

Docetaxel

Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m\^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

DRUG

RhuMab 2C4

Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.

Trial Locations (2)

3075 EA

Rotterdam

SM2 5PT

Sutton

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY